Current Report Filing (8-k)
28 Junho 2023 - 6:01PM
Edgar (US Regulatory)
0001624326
false
0001624326
2023-06-28
2023-06-28
0001624326
PAVM:CommonStockParValue0.001PerShareMember
2023-06-28
2023-06-28
0001624326
PAVM:SeriesZWarrantsToPurchaseCommonStockMember
2023-06-28
2023-06-28
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): June 28, 2023
PAVMED
INC. |
(Exact
Name of Registrant as Specified in Charter) |
Delaware |
|
001-37685 |
|
47-1214177 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
360
Madison Avenue, 25th
Floor, New
York, New
York |
|
10017 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (212) 949-4319
N/A |
(Former
Name or Former Address, if Changed Since Last Report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425). |
|
|
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12). |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)). |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)). |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, Par Value $0.001 Per Share |
|
PAVM |
|
The
Nasdaq Stock Market LLC |
Series
Z Warrants to Purchase Common Stock |
|
PAVMZ |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01. Other Events.
On
June 28, 2023, The Nasdaq Stock Market (“Nasdaq”) notified PAVmed Inc. (the
“Company”) that it would be afforded an additional 180 calendar days (or
until December 26, 2023)
to regain compliance with Nasdaq’s minimum bid price requirement.
As
previously disclosed, on December 29, 2022, the Company received a notification letter from the Nasdaq Listing Qualifications Department
stating that, for the prior 30 consecutive business days (through December 28, 2022), the closing bid price of the Company’s common
stock had been below the minimum of $1 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule
5550(a)(2). The initial notification letter stated that the Company would be afforded 180 calendar days (until June 27, 2023) to regain
compliance, and that the Company could be eligible for additional time. Although the Company did not regain compliance within the initial
180 calendar day period, Nasdaq determined that the Company was eligible for the additional 180 calendar day period to regain compliance.
In
order to regain compliance, the closing bid price of the Company’s common stock must be at least $1 per share for a minimum of
ten consecutive business days during the additional 180 calendar day period. The Company intends to consider all available options to
regain compliance with the Nasdaq listing standards.
The
Nasdaq notification has no effect at this time on the listing of the Company’s common stock or Series Z warrants, which will continue
to trade uninterrupted under the symbols “PAVM” and “PAVMZ,” respectively.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits:
Exhibit
No. |
|
Description |
104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated:
June 28, 2023
|
PAVMED INC. |
|
|
|
|
By: |
/s/
Dennis M. McGrath |
|
|
Dennis
M. McGrath |
|
|
President
and Chief Financial Officer |
PAVmed (NASDAQ:PAVMW)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
PAVmed (NASDAQ:PAVMW)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024
Notícias em tempo-real sobre PAVmed Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Pavmed Inc.